Akeso, Inc. (9926.HK), established in 2012, is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide.

Since our establishment, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.


With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 30 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease, and other major therapeutic areas. Akeso has successfully promoted the commercialization of three innovative biological drugs (one out-licensed drug), 17 assets have entered clinical stage, with 14 clinical trials under pivotal/phase III trial. In June 2022, 开坦尼® (PD-1/CTLA-4 bi-specific antibody, Cadonilimab injection) was approved by the NMPA and became the first tumor dual immune checkpoint inhibitor bi-specific antibody approved for marketing globally. Another Akeso internally discovered and developed oncology product,安尼可® (PD-1 monoclonal antibody, Penpulimab injection) , was granted marketing approval in China in August 2021. In December 2022, the Company out-licensed breakthrough bispecific antibody, ivonescimab (PD-1/VEGF bi-specific antibody, AK112), with up to US$5 Billion total potential deal value to Summit Therapeutics for development and commercialization in the U.S., Canada, Europe, and Japan. 

Through efficient and breakthrough R&D innovation, Akeso always integrate superior global resources, develop the first-in-class and best-in-class new drugs, provide affordable therapeutic antibodies for patients worldwide, and continuously create more commercial and social values so as to become a global leading biopharmaceutical enterprise.